82
Spiro Sertsis: CCIM
Andreas G.: HVT
TSXV: HVT
HVST)
HVST)
P
HVT: Not necessarily. Although that description holds true for the current regulatory framework it has always been United Greeneries plan to supply both the medical and recreational markets. We are currently launching two brands, Captains Choice and Royal High that will eventually cater for the recreational market while we intend to service the medical market with our Satipharm capsules.
CCIM: With its presence in Australia and Germany already in place with Satipharm, are there any plans to export medical marijuana to these countries or others with an approved legal framework within the European Union in the future?
HVT: In 2017, we concentrated on establishing the distribution and launch of our cannabidiol (CBD) dietary supplement capsules throughout Europe. During this time, we have received interest from potential commercial partners across Europe, where medical cannabis legislation is changing, to distribute our products. We are going to explore this in more detail this year.
CCIM: Satipharm AG is currently undertaking Clinical Trials using Satipharm’s proprietary GelpellR technology in drug beads/capsules in delivering CBD both safely and effectively in treating refractory epilepsy in children and also for spasticity experienced by people with Multiple Sclerosis. Last update had these trials into Phase 2. Only two other companies have reach this stage: Insys Therapeutics and GW Pharmaceuticals. Some pretty elite company for Harvest One. Can you please elaborate on the significance of this achievement and what this means for the long-term prospects of the Satipharm products?
HVT: We are delighted to report that enrollment in our refractory epilepsy trial is close to completion. We anticipate reporting results from this trial during 2018. We are very excited to start our clinical trial in patients with multiple sclerosis shortly. These trials are hugely important to Satipharm. Firstly, the data from these trials provide the medical community with critical information to support the use of our products, including dose-response, efficacy and pharmacokinetic data in patients. Over the long term, the data from these trials will help to establish our medical cannabis capsules as one of the premier treatment options available to patients and physicians wherever the legislation will allow their use.